17 related news articles for Lung cancer

Hudson Institute researchers have had some great success in the recent NHMRC Ideas and ARC Discovery Grant rounds.…  Read more

Associate Professor Dan Gough and his team are studying how to make these cold tumours visible to the immune system and prevent them spreading to other parts of the body.…  Read more

Associate Professor Dan Gough and his team have developed sophisticated models of lung cancer which allow them to model disease progression and observe response to current treatments in patients.…  Read more

Associate Professor Daniel Gough has received the first ever PASO Fellowship at Hudson Institute, securing the future of his ground-breaking lung cancer research.…  Read more

Hudson Institute researchers have had some great success in the recent NHMRC Grant rounds.…  Read more

Researchers at Hudson Institute of Medical Research have shown a new drug that is incredibly effective in treating small cell lung cancer – doubling the usual survival time.…  Read more

A new understanding of the causes of small cell lung cancer (SCLC) could lead to more personalised treatments and lower mortality from this deadly disease.…  Read more

Six Early Career Researchers have been chosen for the 2021 Hudson Institute Emerging Leaders program.…  Read more

Hudson Institute scientists have paved the way to potentially test new treatments for chronic obstructive pulmonary disease (COPD) and emphysema, following a discovery of the molecular drivers of these lung diseases.…  Read more

Congratulations to Dr Mohamed Saad, who has been awarded a Cancer Council Victoria (CCV) Postdoctoral Cancer Research Fellowship to inform the design of better treatment approaches in lung cancer.…  Read more

Congratulations to Dr Daniel Gough for receiving a Mid-Career Research Fellowship from the Victorian Cancer Agency (VCA) for his research in developing new therapies for small cell lung cancer (SCLC).…  Read more

Improved treatments for a range of cancers could be possible following a discovery that stomach cancer is mainly driven by a different process than previously believed.…  Read more

The development of a drug to treat the most common type of lung cancer is a step closer …  Read more

A naturally occurring hormone could help make chemotherapy much more effective for many Australians with lung cancer, according to new findings from Sydney and Melbourne researchers. And the hormone – known as follistatin – also appears to prevent kidney damage, a serious side effect of chemotherapy. The promising new ‘two birds, one stone’ treatment approach, which was…  Read more

Lung cancer is the leading cause of cancer death worldwide, and is frequently associated with cachexia. Cachexia is a devastating syndrome of weight and muscle wasting, affecting as many as 80 per cent of advanced cancer patients.…  Read more

Scientists from across the world discussing immunology research…  Read more

Lung cancer and emphysema could be diagnosed earlier and targeted with an existing drug, vastly improving patient outcomes, researchers at Hudson Institute of Medical Research have discovered…  Read more